Mycoplasma genitalium (M. gen) Treatment
Covered by Aetna in California

WHEN RESISTANCE TESTING NOT AVAILABLE: Doxycycline 100mg orally twice daily × 7 days (Step 1 — organism load reduction), FOLLOWED BY moxifloxacin 400mg orally once daily × 7 days (Step 2) — per CDC STI Treatment Guidelines (current standard through 2024). This is the preferred regimen when M. genitalium macrolide resistance testing is unavailable or the test shows macrolide resistance. WHEN MACROLIDE-SENSITIVE (resistance testing available): Doxycycline 100mg twice daily × 7 days, FOLLOWED BY azithromycin 1g orally on Day 1, THEN azithromycin 500mg daily × 3 additional days (2.5g total azithromycin over 4 days)

In settings where moxifloxacin cannot be used (fluoroquinolone allergy, concern for cardiac QTc prolongation) AND resistance testing unavailable: doxycycline 100mg BID × 7 days FOLLOWED BY azithromycin 1g on Day 1 then 500mg × 3 days, WITH test of cure at 21 days post-completion. Pristinamycin (not FDA-approved in US) used in Europe for refractory cases. Sitafloxacin (available in Asia) shows activity but not available in US.

Yes — doxycycline 100mg Tier 1 generic ($4–$10 per 14 capsules); azithromycin Tier 1 generic ($5–$10 for a 1g dose or full 2.5g course); moxifloxacin 400mg Tier 1 generic (~$20–$40 for 7 tablets). All covered without prior authorization on Aetna CA commercial plans. Total medication cost for full two-step regimen: typically $25–$55 with Tier 1 copays.

Per CDC STI Treatment Guidelines, a test of cure (TOC) using M. genitalium NAAT performed no earlier than 21 days after completing therapy is recommended when: (1) the doxycycline + azithromycin regimen (not moxifloxacin) was used without resistance testing, or (2) the patient remains symptomatic. Routine TOC is not needed after doxycycline + moxifloxacin in asymptomatic patients. High rates of macrolide resistance — approaching 50% in some US MSM populations — are the main driver of the shift away from empiric azithromycin monotherapy. Moxifloxacin achieves >90% cure rates in macrolide-resistant M. genitalium. QTc prolongation risk with moxifloxacin is clinically relevant — Dr. Bhavsar reviews baseline cardiac history and concurrent QT-prolonging medications.

The two-step regimen (doxycycline first, then azithromycin or moxifloxacin) is designed to address the M. genitalium resistance problem. Taking azithromycin alone or as a single dose selects for mutants with macrolide resistance, producing treatment failure and further resistance spread — a major driver of the current 40–50% macrolide resistance rate in many US populations. Starting with 7 days of doxycycline first reduces the total organism burden and partially clears susceptible organisms, then the second-step macrolide or moxifloxacin targets the remaining organisms. This two-step strategy achieves cure rates above 90% compared to 60–70% with single-agent azithromycin in macrolide-resistant infections.

Generic moxifloxacin 400mg tablets are Tier 1 on the Aetna CA formulary with no prior authorization required for a standard 7-day course. The typical cost is $20–$40 at major California pharmacies on a Tier 1 copay. There is no step therapy requirement to try another antibiotic before moxifloxacin for M. genitalium — the CDC explicitly recommends moxifloxacin as definitive therapy for macrolide-resistant infection. If your specific plan's formulary differs, Dr. Bhavsar documents the medical necessity based on CDC guidelines.

M. genitalium NAAT testing is increasingly available at major reference labs including Quest Diagnostics and LabCorp, both of which have numerous patient service centers throughout California. At-home STI panels from some telehealth services now include M. genitalium. TDMD can send a lab order to your nearest California Quest or LabCorp location. Not all urgent care or in-office STI panels include M. genitalium — it is often left off routine panels because it is tested separately from chlamydia/gonorrhea. If you have persistent urethritis or cervicitis after standard chlamydia treatment, requesting an M. genitalium NAAT is appropriate.

Yes, simultaneous partner treatment is strongly recommended to prevent re-infection. Under California's EPT law, Dr. Bhavsar can write a prescription for your partner(s) for the M. genitalium treatment regimen without the partner appearing for an examination — EPT in California covers all bacterial STIs including M. genitalium (the EPT statute covers 'sexually transmitted infections' broadly). Simultaneous treatment of both partners is especially important for M. genitalium because treatment failure from reinfection is a major cause of persistent positive results. Partners should also abstain from sex until both have completed their full treatment course.

Yes. Aetna commercial plans cover telehealth visits for Mycoplasma genitalium (M. gen) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your mycoplasma genitalium treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your mycoplasma genitalium treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.